Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 6
2004 5
2005 8
2006 6
2007 4
2008 7
2009 7
2010 11
2011 12
2012 13
2013 10
2014 14
2015 6
2016 7
2017 6
2018 3
2019 6
2020 4
2021 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenicity of biopharmaceuticals.
Kessler M, Goldsmith D, Schellekens H. Kessler M, et al. Among authors: schellekens h. Nephrol Dial Transplant. 2006 Oct;21 Suppl 5:v9-12. doi: 10.1093/ndt/gfl476. Nephrol Dial Transplant. 2006. PMID: 16959792 Review.
Safety and efficacy of biosimilars in oncology.
Schellekens H, Smolen JS, Dicato M, Rifkin RM. Schellekens H, et al. Lancet Oncol. 2016 Nov;17(11):e502-e509. doi: 10.1016/S1470-2045(16)30374-6. Lancet Oncol. 2016. PMID: 27819248 Review.
Towards a sustainable system of drug development.
Moors EHM, Cohen AF, Schellekens H. Moors EHM, et al. Among authors: schellekens h. Drug Discov Today. 2014 Nov;19(11):1711-1720. doi: 10.1016/j.drudis.2014.03.004. Epub 2014 Mar 19. Drug Discov Today. 2014. PMID: 24657626 Review.
Immunogenicity of rDNA-derived pharmaceuticals.
Ryff JC, Schellekens H. Ryff JC, et al. Among authors: schellekens h. Trends Pharmacol Sci. 2002 Jun;23(6):254-6. doi: 10.1016/s0165-6147(02)02024-2. Trends Pharmacol Sci. 2002. PMID: 12084625 Review.
The safety of switching between therapeutic proteins.
Ebbers HC, Muenzberg M, Schellekens H. Ebbers HC, et al. Among authors: schellekens h. Expert Opin Biol Ther. 2012 Nov;12(11):1473-85. doi: 10.1517/14712598.2012.711308. Epub 2012 Jul 31. Expert Opin Biol Ther. 2012. PMID: 22849511 Review.
Immunogenicity of bone morphogenetic proteins.
Hwang CJ, Vaccaro AR, Lawrence JP, Hong J, Schellekens H, Alaoui-Ismaili MH, Falb D. Hwang CJ, et al. Among authors: schellekens h. J Neurosurg Spine. 2009 May;10(5):443-51. doi: 10.3171/2009.1.SPINE08473. J Neurosurg Spine. 2009. PMID: 19442006 Review.
Biosimilars or semi-similars?
Schellekens H, Moors E. Schellekens H, et al. Nat Biotechnol. 2015 Jan;33(1):19-20. doi: 10.1038/nbt.3083. Nat Biotechnol. 2015. PMID: 25574627 No abstract available.
123 results